Ursula A. Matulonis, MD, discusses the impact of PARP inhibitors on ovarian cancer treatment.
Ursula Matulonis, MD
Articles by Ursula Matulonis, MD
Ursula Matulonis, MD, medical director of Gynecologic Oncology at Dana-Farber Cancer Institute, discusses two upcoming trials for both platinum-resistant and platinum-sensitive recurrent ovarian cancer.
Latest Updated Articles
An Abundance of PARP Inhibitors are Changing Ovarian Cancer TreatmentPublished: March 10th 2022 | Updated:
Dr. Ursula Matulonis on Phase III Trials Examining Cediranib Plus Olaparib in Ovarian CancerPublished: March 24th 2016 | Updated: